FibroGen (FGEN) Misses Q3 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
FibroGen Reports Third Quarter 2019 Financial Results
November 11, 2019 4:01 PM ESTRoxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
Time to event endpoints using Cox model, ITT analysis NDD (OLYMPUS, ANDES, ALPS), N=4270... MoreFibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
November 8, 2019 2:10 PM ESTRoxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+
Time to event endpoints using Cox model, ITT analysis* NDD (OLYMPUS, ANDES, ALPS), N=4270*ITT analysis agreed with the FDA... More